TRANSLATIONAL MEDICINE AND THE PULMONOLIGIST

Scientific Rationale

Good studies of translational medicine are mandatory to reach a better understanding, at the molecular level, of the pathogenesis of lung diseases. We still have a significant unmet needs in the pathogenesis and pharmacological personalised treatment of difficult-to-control asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF) and idiopathic pulmonary arterial hypertension (IPAH). Collectively these lung diseases represent a major cause of morbidity and/or mortality worldwide. In addition there are molecular links, still largely under investigated, between COPD, lung, cancer and IPF all smoking-related disease but with different clinical-pathological expressions. It is particularly relevant that In a large longitudinal study of asymptomatic patients with mild-to-moderate COPD, ~33% of subjects died of lung cancer over ~15 years suggesting that lung cancer is a leading cause of morbidity and mortality in COPD patients.These patients share a common environmental risk factor (smoking) and a genetic predisposition represented by the incidence of these diseases in only a fraction of smokers. COPD is also a major independent risk factor for lung carcinoma, among smokers. Sepsis is a major cause of ARDS and this deadly disease can be considered another orphan disease due to the paucity of studies on its pathogenesis. IPAH is an uncommon lethal disease and we need to develop better drugs to modify its natural history.

For all these reasons the aim of this meeting is to gather together Italian and International experts in the field of these lung diseases to discuss in depth the cutting edge translational medicine research performed in these different diseases and to coordinate global research network efforts to promote a better knowledge in their pathogenesis and to obtain new targets for rationale drug development.

Downolad the brochure

Scientific Organiser

Prof Gaetano Caramori MD, PhD

Dipartimento di Scienze Mediche, Sezione di Medicina Interna e Cardiorespiratoria

Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree

e Patologie Fumo-Correlate (CEMICEF), Università di Ferrara, Italy

Continuing Medical Educaltion

This is a CME event accredited for 100 PARTICIPANTS (graduated in Medicine and Surgery)

Disciplines: PULMONOLOGY; ALLERGOLOGY AND CLINICAL IMMUNOLOGY, GERIATRICS; INTERNAL MEDICINE; OCCUPATIONAL MEDICINE; GENERAL PRACTITIONERS [FAMILY (PRIMARY CARE) DOCTORS].

CME credits assigned: 8

To obtain the CME credits is mandatory to participate to the entire duration of the event (8 hours) to sign the CME register (at the beginning and at the end of the meeting) and to pass the final evaluation questionnaire.

Official language: ENGLISH, no translation provided

CME Provider

	Euromediform srl Via A. Cesalpino 5/B 50134 Firenze tel. 055 79.54.222 fax 055 79.54.260

Venue of the Meeting

	AULA MAGNA Azienda Ospedaliero-Universitaria "Arcispedale S. Anna" Via Aldo Moro, 8 - 44124 Cona (FE), Italy     To reach the venue of the meeting please visit the web site: http://www.ospfe.it/carta-dei-servizi/come-arrivare-al-sant2019anna-a-cona-in-via-a.-moro-8

Registration

ON SITE REGISTRATION ONLY AVAILABLE FORM OCTOBER 27TH.

Organizing Secretariat

	CONSORZIO FUTURO IN RICERCA Ufficio Convegni ed Attività Formative Via Saragat 1 - Blocco B - 1° piano - 44122 Ferrara - Italy Tel. +39 0532 762404 - Fax +39 0532 767347 - E-mail convegni@unife.it